Arcellx Shareholder Suit Targets $115 Cash and $5 CVR Gilead Deal
Arcellx shareholders face a proposed $115 per share cash sale to Gilead Sciences plus a $5 contingent value right tied to future milestones and potentially restrictive deal terms. Halper Sadeh LLC is probing possible securities law violations and fiduciary breaches alleging insiders stand to gain benefits unavailable to ordinary investors.
1. Transaction Details
Arcellx agreed to sell to Gilead Sciences for $115 per share in cash plus a contingent value right of $5 per share upon achievement of specified milestones. This structure sets initial deal value at $120 per share subject to future performance triggers.
2. Investigation Allegations
Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties by Arcellx’s board and insiders. The firm alleges proposed terms may limit superior competing offers and grant substantial benefits to insiders unavailable to ordinary shareholders.
3. Shareholder Options
Shareholders are encouraged to consult Halper Sadeh LLC to explore legal rights and options at no upfront cost. Potential relief may include increased consideration, additional disclosures or other benefits, with fees contingent on successful outcomes.